A new blood test could determine a woman’s dementia risk as early as 25 years before symptoms emerge.

That’s according to new research from the University of California San Diego, which found that a specific biomarker protein associated with early pathological processes of Alzheimer’s disease was “strongly linked” to future dementia risk.

The researchers analyzed blood samples from 2,766 participants in the Women’s Health Initiative Memory Study in the late 1990s, according to the study’s press release. 

KEY FITNESS MEASURE IS STRONG PREDICTOR OF LONGEVITY AFTER CERTAIN AGE, STUDY FINDS

The women ranged from 65 to 79 years of age and showed no signs of cognitive decline at the start of the study.

After tracking the participants for up to 25 years, the researchers concluded that the biomarker phosphorylated tau 217 (p-tau217) was “strongly associated” with future mild cognitive impairment and dementia. 

Women who had higher levels of p-tau217 at the beginning of the study were “much more likely” to develop the disease. The findings were published today in JAMA Network Open.

“The key takeaway is that our study suggests it may be possible to detect risk of dementia two decades in advance using a simple blood test in older women,” first author Aladdin H. Shadyab, a UC San Diego associate professor of public health and medicine, told Fox News Digital. 

“These biomarkers may help us identify who is at greatest risk and develop strategies to delay or prevent dementia.”

“Our findings show that the blood biomarker p-tau217 could help identify individuals at higher risk for dementia long before symptoms begin,” he added.

This long lead time could open the door to earlier prevention strategies and more targeted monitoring, rather than waiting until memory problems are already affecting daily life, according to Shadyab.

“As the research advances, these biomarkers may help us identify who is at greatest risk and develop strategies to delay or prevent dementia,” he said.

This risk relationship wasn’t the same across the board, however. Women over 70 with higher p-tau217 levels had “poorer cognitive outcomes” compared to those under 70, as did those with the APOE ε4 gene, which is a known risk factor for Alzheimer’s disease.

The study also found that p-tau217 was a stronger predictor of dementia in women who were randomly assigned to receive estrogen and progestin hormone therapy compared to those who received a placebo.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

“Blood-based biomarkers like p-tau217 are especially promising because they are far less invasive and potentially more accessible than brain imaging or spinal fluid tests,” said senior author Linda K. McEvoy, senior investigator at Kaiser Permanente Washington Health Research Institute and professor emeritus at the Herbert Wertheim School of Public Health, in the release. 

“This is important for accelerating research into the factors that affect the risk of dementia and for evaluating strategies that may reduce risk.”

Blood tests for Alzheimer’s disease are still being studied and are not recommended for routine screening in people without symptoms, Shadyab noted. 

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

More research is needed before this approach can be considered for clinical use prior to cognitive symptoms. 

Future studies should investigate how other factors — like genetics, hormone therapy and age-related medical conditions — might interact with plasma p-tau217, the researchers added.

CLICK HERE FOR MORE HEALTH STORIES

“The study examined only older women, so the findings may not necessarily apply to men or younger populations,” Shadyab noted. “We also examined overall dementia outcomes rather than specific subtypes such as Alzheimer’s disease.”

For women over 60, muscle strength plays a critical role in longevity, a new study confirms.

Researchers at the University at Buffalo, New York, followed more than 5,000 women between the ages of 63 and 99, finding that those with greater muscle strength had a significantly lower risk of death over an eight-year period.

The findings were published in JAMA Network Open.

EXERCISE AFFECTS THE HEART IN A HIDDEN, POWERFUL WAY BY REWIRING NERVES, STUDY FINDS

Muscle function was measured using grip strength and how quickly participants could complete five unassisted sit-to-stand chair raises. 

These are two tests commonly used in clinical settings to evaluate muscle function in older adults, the researchers noted.

“In a community cohort of ambulatory older women, muscular strength was associated with significantly lower mortality rates, even when we accounted for usual physical activity and sedentary time measured using a wearable monitor, gait speed and blood C-reactive protein levels,” study lead author Michael LaMonte, research professor of epidemiology and environmental health at the University at Buffalo, told Fox News Digital.

“Movement is the key — just move more and sit less.”

Advertisement

Many earlier studies did not include those objective measurements, making it difficult to determine whether muscle strength itself was linked to longevity, according to LaMonte. “Our study was able to better isolate the association between strength and death in later life,” he added.

Even for women who don’t get the recommended amount of aerobic physical activity, which is at least 150 minutes per week, muscle strength remained important for longevity, the researchers found.

“The findings of lower mortality in those who had higher strength but were not meeting current national guidelines on aerobic activity were somewhat intriguing,” LaMonte said.

CLICK HERE FOR MORE LIFESTYLE STORIES

Federal guidelines recommend strengthening activities one to two days per week, targeting major muscle groups.

Resistance training does not have to require a gym membership, LaMonte noted. These exercises can be performed using free weights, resistance bands, bodyweight movements or even household items, such as soup cans.

“Movement is the key — just move more and sit less,” he said. “When we can no longer get out of the chair and move around, we are in trouble.”

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

LaMonte acknowledged several limitations of the study. The researchers assessed muscle strength in older age but did not explore how earlier levels in adulthood might influence long-term health outcomes.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

“We were not able to understand how strength and mortality relate in younger ages,” he said, noting that future research should explore whether building strength earlier could have an even greater impact on longevity.

Compounds found in cannabis could provide a new roadmap for treating the world’s most common chronic liver disorder, according to a study released by the Hebrew University of Jerusalem.

The research, published in the British Journal of Pharmacology, found that cannabidiol (CBD) and cannabigerol (CBG) significantly reduced liver fat and improved metabolic health in experimental models.

CBD is the more widely studied non-intoxicating cannabinoid, while CBG is a less common “precursor” cannabinoid from which CBD is formed.

MYSTERIOUS MARIJUANA-LINKED VOMITING DISORDER GETS OFFICIAL WHO CODE AS ER CASES JUMP

Unlike THC, the primary psychoactive component in cannabis, these compounds do not produce a “high,” making them viable candidates for long-term medical treatment, the study suggests.

Metabolic dysfunction-associated steatotic liver disease (MASLD) currently affects approximately one-third of the global adult population, according to health data.

The condition, which is closely linked to obesity and insulin resistance, has few approved pharmaceutical treatments, the researchers said, leaving patients to rely largely on lifestyle changes that can be difficult to maintain. 

“Our findings identify a new mechanism by which CBD and CBG enhance hepatic energy and lysosomal function,” said lead study author Joseph Tam, director of the Multidisciplinary Center for Cannabinoid Research at Hebrew University, in a press release.

MARIJUANA COMPOUND MAY HELP PREVENT DEMENTIA WHEN PAIRED WITH COMMON DRUG

The study highlights a process called “metabolic remodeling,” in which the cannabis compounds created a “backup battery” for the liver by increasing levels of phosphocreatine, a high-energy molecule stored in muscle cells.

This energy reserve helps the organ function under the stress of a high-fat diet, which was an unexpected discovery, the team noted.

The researchers also found that CBD and CBG restored the activity of “cellular cleaning crews” known as cathepsins, enzymes that work within the cell’s recycling centers to break down harmful fats and waste.

With this process, the liver was better able to clear out dangerous lipids, including triglycerides and ceramides, which are known to trigger inflammation, the study showed.

CLICK HERE FOR MORE HEALTH STORIES

While both compounds were effective, CBG showed more robust results in certain areas, such as reducing total body fat mass, lowering “bad” LDL cholesterol and improving insulin sensitivity.

Researchers say this study opens a new path for using plant-based compounds to treat metabolic diseases by focusing on how cells manage energy and waste.

Limitations and caveats

Despite the promising results, the research team cautioned that the study was conducted in a controlled experimental environment. Further clinical trials are necessary to determine the proper application for human patients.

Other recent studies have pointed to potential issues with using cannabis as a medical tool.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

A major analysis published in JAMA examined more than 2,500 scientific papers from the last 15 years, including other reviews, clinical trials and guidelines focused on medical marijuana.

The 2025 review highlighted significant gaps between public perception and scientific evidence regarding cannabis’ effectiveness for most medical conditions.

The researchers concluded that there are very few conditions for which cannabinoid therapies have clear, well-established benefits backed by high-quality clinical data.

“Whenever a substance is widely used, there is likely to be a very wide set of outcomes,” Alex Dimitriu, MD, who is double board-certified in psychiatry and sleep medicine and founder of Menlo Park Psychiatry & Sleep Medicine, previously told Fox News Digital. “This study points to the reality that this widely used substance is not a panacea.”

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

The strongest evidence supports FDA-approved cannabinoid medications for treating specific conditions, including HIV/AIDS-related appetite loss, chemotherapy-induced nausea and vomiting, and certain severe pediatric seizure disorders, according to the review.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Anyone interested in using marijuana for medical purposes should speak to a healthcare provider to discuss potential risks and benefits.